Skip to main content
Fig. 2 | Malaria Journal

Fig. 2

From: Effectiveness and safety of artemether–lumefantrine versus artesunate–amodiaquine for unsupervised treatment of uncomplicated falciparum malaria in patients of all age groups in Nanoro, Burkina Faso: a randomized open label trial

Fig. 2

Kaplan–Meier survival curve of risk of recrudescence. The figure shows the percentage of patients with recrudescent infection during the 28 days follow-up. The blue line indicates patients treated with artemether–lumefantrine (AL), the red line indicates patients treated with artesunate–amodiaquine (ASAQ)

Back to article page

Malaria Journal

ISSN: 1475-2875

Contact us